Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 85 across all filing types
Latest filing 2025-08-29 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2025
Interim / Quarterly Report Classification · 100% confidence The document is an 'Interim Results Announcement' for Sunshine Lake Pharma Co., Ltd. for the six months ended 30 June 2025. It contains detailed financial highlights (revenue, gross profit, loss), management discussion and analysis (MDA), and operational updates regarding R&D pipelines. As it provides comprehensive financial data and analysis for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. H2 2025
2025-08-29 English
INSIDE INFORMATION PROPOSED IMPLEMENTATION OF H SHARE FULL CIRCULATION BY THE COMPANY
Share Issue/Capital Change Classification · 85% confidence The document is a corporate announcement by Sunshine Lake Pharma regarding the proposed conversion of its domestic shares into H shares and the subsequent application for listing and dealing on the Hong Kong Stock Exchange. This is a structural change in the company’s share capital, rather than an earnings release, management report, voting results, or financing update. It involves a change to the company’s share classes and listing status, which falls under the definition of a Share Issue/Capital Change (Code: SHA).
2025-08-29 English
FORM OF PROXY FOR THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a form of proxy for shareholders to vote at the 2025 first extraordinary general meeting, providing instructions on appointing proxies and voting on resolutions. This is material sent to shareholders to solicit votes, which corresponds to the Proxy Solicitation & Information Statement category (PSI).
2025-08-19 English
NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a formal notice of an Extraordinary General Meeting (EGM) including the meeting details, proposed resolutions (granting a general mandate for share allotment), and proxy appointment instructions. It is clearly proxy solicitation material sent to shareholders to request votes on the resolution, rather than the actual share issuance or financial report. This aligns with the "Proxy Solicitation & Information Statement" category.
2025-08-19 English
PROPOSED GRANT OF GENERAL ISSUE MANDATE AND NOTICE OF THE 2025 FIRST EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a shareholder circular for an Extraordinary General Meeting (EGM) containing a letter from the Board, definitions, explanatory statements on the proposed General Issue Mandate, and the formal notice of the EGM with proxy instructions. It is clearly sent to shareholders to provide information on resolutions and to solicit votes. This corresponds to a Proxy Solicitation & Information Statement (PSI).
2025-08-19 English
NOTICE OF BOARD MEETING
Regulatory Filings Classification · 82% confidence The document is a short Hong Kong Exchanges announcement notifying investors of a forthcoming board meeting to consider interim results and dividend. It does not present an actual report, earnings, or major corporate change, nor does it announce publication of a report. There is no change in management, no financial results disclosed, and no governance document attached. It therefore falls into the general fallback category for miscellaneous regulatory filings: RNS.
2025-08-19 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.